Home / Business and Economy / Lilly Ordered to Pay Nektar $90M in Drug Deal Dispute
Lilly Ordered to Pay Nektar $90M in Drug Deal Dispute
25 Sep
Summary
- Eli Lilly must pay Nektar Therapeutics $90 million.
- The payment is for breaking an agreement on an autoimmune drug candidate.
- A federal jury in California made the determination in the case.
A federal jury in California has ruled that Eli Lilly & Co. must pay Nektar Therapeutics $90 million. This ruling is a consequence of Eli Lilly breaking a contractual agreement related to an autoimmune drug candidate that both companies had developed collaboratively. The case, Nektar Therapeutics v. Eli Lilly & Co, was heard in the US District Court for the Northern District of California.
The jury's determination underscores the importance of adhering to partnership agreements within the pharmaceutical industry. This outcome signifies a major development in the legal proceedings between the two companies, directly impacting their financial standings and future collaborations. The specific details of the broken agreement and the drug candidate's development status were central to the jury's decision.
